PET and SPECT in brain tumors and epilepsy

Neurosurgery Clinics of North America

Volumn 22, Issue 2, 2011, Pages 169-184

  Horky, Laura L ^a   Treves, S Ted ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Brain tumor; Epilepsy; Molecular imaging; Positron emission tomography

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 4 AMINOBUTYRIC ACID RECEPTOR; 6 FLUORODOPA F 18; CARBON ALPHA METHYL TRYPTOPHAN C 11; FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18; INDIUM PENTREOTIDE IN 111; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; O (2 FLUOROETHYL)TYROSINE F 18; RADIOPHARMACEUTICAL AGENT; SEROTONIN RECEPTOR; THALLIUM 201; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; BRAIN BLOOD FLOW; BRAIN TUMOR; CANCER GRADING; CELL PROLIFERATION; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMAN; IMAGING; MEDICAL HISTORY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RADIATION NECROSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR RECURRENCE;

BRAIN; BRAIN NEOPLASMS; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; EPILEPSY; FLUMAZENIL; FLUORODEOXYGLUCOSE F18; GABA MODULATORS; HUMANS; NECROSIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79952828599     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2010.12.003     Document Type: Review

References (110)

1. Central Brain Tumor Registry of the United States (CBTRUS) Statistical report: primary brain tumors in the United States, 1998-2002 2005, North American Brain Tumor Coalition, Available at:, Accessed March 1, 2010. http://www.nabraintumor.org/facts.html.
2. Cancer facts and figures Report 2009. American Cancer Society; 2009. Available at: Accessed March 1, 2010. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2009.
3. Medical encyclopedia: metastatic brain tumor. Medline plus; 2006. Available at: Accessed March 1, 2010. http://www.nlm.gov/medlineplus/print/ency/article/000769.htm.
4. Phelps M.E., Hoffman E.J., Mullani N.A., et al. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 1975, 16(3):210-224.
5. Czernin J., Dahlbom M., Ratib O., et al. Atlas of PET/CT imaging in oncology 2004, Springer-Verlag, Berlin.
6. Catana C., Wu Y., Judenhofer M.S., et al. Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. J Nucl Med 2006, 47(12):1968-1976.
7. Di Chiro G., DeLaPaz R.L., Brooks R.A., et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982, 32(12):1323-1329.
8. Herholz K., Herscovitch P., Heiss W.D. NeuroPET: PET in neuroscience and clinical neurology 2004, Springer-Verlag, Berlin.
9. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314.
10. Murovic J.A., Nagashima T., Hoshino T., et al. Pediatric central nervous system tumors: a cell kinetic study with bromodeoxyuridine. Neurosurgery 1986, 19(6):900-904.
11. Fulham M.J., Radu E.W., Hausmann O., et al. Neuroimaging of juvenile pilocytic astrocytomas: an enigma. Radiology 1993, 189(1):221-225.
12. Roelcke U., Radu E.W., Hausmann O., et al. Tracer transport and metabolism in a patient with juvenile pilocytic astrocytoma. A PET study. J Neurooncol 1998, 36(3):279-283.
13. Strauss L.G., Conti P.S. The applications of PET in clinical oncology. J Nucl Med 1991, 32(4):623-648. [discussion 649-50].
14. Huang S.C. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 2000, 27(7):643-646.
15. Delbeke D., Meyerowitz C., Lapidus R.L., et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995, 195(1):47-52.
16. Padma M.V., Said S., Jacobs M., et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003, 64(3):227-237.
17. Hustinx R., Pourdehnad M., Kaschten B., et al. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am 2005, 43(1):35-47.
18. Langleben D.D., Segall G.M. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000, 41(11):1861-1867.
19. Arnold S.M., Patchell R.A. Diagnosis and management of brain metastases. Hematol Oncol Clin North Am 2001, 15(6):1085-1107. vii.
20. Janus T.J., Kim E.E., Tilbury R., et al. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993, 33(5):540-548.
21. Ricci P.E., Karis J.P., Heiserman J.E., et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?. AJNR Am J Neuroradiol 1998, 19(3):407-413.
22. Valk P.E., Budinger T.F., Levin V.A., et al. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 1988, 69(6):830-838.
23. Kim E.E., Chung S.K., Haynie T.P., et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics 1992, 12(2):269-279.
24. Kahn D., Follett A., Bushnell D.L., et al. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. AJR Am J Roentgenol 1994, 163(6):1459-1465.
25. Chao S.T., Suh J.H., Raja S., et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001, 96(3):191-197.
26. Spence A.M., Muzi M., Mankoff D.A., et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 2004, 45(10):1653-1659.
27. Horky L.L., Hsiao M.E., Weiss E.S., et al. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol 2010, [Epub ahead of print].
28. Chen W., Cloughesy T., Kamdar N., et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 2005, 46(6):945-952.
29. Chen W., Delaloye S., Silverman D.H., et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007, 25(30):4714-4721.
30. Muzi M., Spence A.M., O'Sullivan F., et al. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. J Nucl Med 2006, 47(10):1612-1621.
31. Herholz K., Holzer T., Bauer B., et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998, 50(5):1316-1322.
32. Floeth F.W., Pauleit D., Sabel M., et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 2007, 48(4):519-527.
33. Pirotte B., Goldman S., Massager N., et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 2004, 45(8):1293-1298.
34. Levivier M., Wikler D., Massager N., et al. The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. J Neurosurg 2002, 97(Suppl 5):542-550.
35. Levivier M., Massager N., Wikler D., et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 2004, 45(7):1146-1154.
36. Langen K.J., Jarosch M., Muhlensiepen H., et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol 2003, 30(5):501-508.
37. Weber W.A., Wester H.J., Grosu A.L., et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000, 27(5):542-549.
38. Grosu A.L., Weber W.A. PET for radiation treatment planning of brain tumours. Radiother Oncol 2010, 96(3):325-327.
39. Garnett E.S., Firnau G., Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983, 305(5930):137-138.
40. Chen W., Silverman D.H., Delaloye S., et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006, 47(6):904-911.
41. Rachinger W., Goetz C., Popperl G., et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005, 57(3):505-511. [discussion: 505-11].
42. Popperl G., Kreth F.W., Mehrkens J.H., et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 2007, 34(12):1933-1942.
43. Schiepers C., Chen W., Cloughesy T., et al. 18F-FDOPA kinetics in brain tumors. J Nucl Med 2007, 48(10):1651-1661.
44. Bruehlmeier M., Roelcke U., Schubiger P.A., et al. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med 2004, 45(11):1851-1859.
45. Valk P.E., Mathis C.A., Prados M.D., et al. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992, 33(12):2133-2137.
46. Gray L.H., Conger A.D., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953, 26(312):638-648.
47. Di Chiro G., Hatazawa J., Katz D.A., et al. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 1987, 164(2):521-526.
48. Ancri D., Basset J.Y., Lonchampt M.F., et al. Diagnosis of cerebral lesions by thallium 201. Radiology 1978, 128(2):417-422.
49. Mountz J.M., Raymond P.A., McKeever P.E., et al. Specific localization of thallium 201 in human high-grade astrocytoma by microautoradiography. Cancer Res 1989, 49(14):4053-4056.
50. Kaplan W.D., Takvorian T., Morris J.H., et al. Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. J Nucl Med 1987, 28(1):47-52.
51. Maria B.L., Drane W.B., Quisling R.J., et al. Correlation between gadolinium-diethylenetriaminepentaacetic acid contrast enhancement and thallium-201 chloride uptake in pediatric brainstem glioma. J Child Neurol 1997, 12(6):341-348.
52. Black K.L., Hawkins R.A., Kim K.T., et al. Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg 1989, 71(3):342-346.
53. Rubinstein R., Karger H., Pietrzyk U., et al. Use of 201Thallium brain SPECT, image registration, and semi-quantitative analysis in the follow-up of brain tumors. Eur J Radiol 1996, 21(3):188-195.
54. Dierckx R.A., Martin J.J., Dobbeleir A., et al. Sensitivity and specificity of thallium-201 single-photon emission tomography in the functional detection and differential diagnosis of brain tumours. Eur J Nucl Med 1994, 21(7):621-633.
55. Kline J.L., Noto R.B., Glantz M. Single-photon emission CT in the evaluation of recurrent brain tumor in patients treated with gamma knife radiosurgery or conventional radiation therapy. AJNR Am J Neuroradiol 1996, 17(9):1681-1686.
56. Lorberboym M., Mandell L.R., Mosesson R.E., et al. The role of thallium-201 uptake and retention in intracranial tumors after radiotherapy. J Nucl Med 1997, 38(2):223-226.
57. Tomura N., Hirano H., Kato H., et al. Unexpected accumulation of thallium-201 in cerebral infarction. J Comput Assist Tomogr 1998, 22(1):126-129.
58. Soler C., Beauchesne P., Maatougui K., et al. Technetium-99 m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. Eur J Nucl Med 1998, 25(12):1649-1657.
59. Maffioli L., Gasparini M., Chiti A., et al. Clinical role of technetium-99 m sestamibi single-photon emission tomography in evaluating pretreated patients with brain tumours. Eur J Nucl Med 1996, 23(3):308-311.
60. Stefanescu C., Meignan M., Rusu V. Rev Med Chir Soc Med Nat Iasi 1995, 99(3-4):99-107. [in French].
61. O'Tuama L.A., Treves S.T., Larar J.N., et al. Thallium-201 versus technetium-99 m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison. J Nucl Med 1993, 34(7):1045-1051.
62. Jeong H.J., Chung J.K., Kim Y.K., et al. Usefulness of whole-body (18)F-FDG PET in patients with suspected metastatic brain tumors. J Nucl Med 2002, 43(11):1432-1437.
63. National Institutes of Health Consensus Conference. Surgery for epilepsy. JAMA 1990, 264(6):729-733.
64. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981, 22(4):489-501.
65. Goffin K. Neuronuclear assessment of patients with epilepsy. Semin Nucl Med 2008, 38(4):227-239.
66. Wiebe S., Blume W.T., Girvin J.P., et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001, 345(5):311-318.
67. Elsharkawy A.E., Pannek H, Schulz R., et al. Outcome of extratemporal epilepsy surgery experience of a single center. Neurosurgery 2008, 63(3):516-525. [discussion 525-6].
68. Berkovic S.F., McIntosh A.M., Kalnins R.M., et al. Preoperative MRI predicts outcome of temporal lobectomy: an actuarial analysis. Neurology 1995, 45(7):1358-1363.
69. Bien C.G., Szinay M., Wagner J., et al. Characteristics and surgical outcomes of patients with refractory magnetic resonance imaging-negative epilepsies. Arch Neurol 2009, 66(12):1491-1499.
70. Knowlton R.C. The role of FDG-PET, ictal SPECT, and MEG in the epilepsy surgery evaluation. Epilepsy Behav 2006, 8(1):91-101.
71. Treves S.T. Pediatric nuclear medicine/PET 2007, Springer, New York, xvii, p. 538. 3rd edition.
72. Lee S.K., Lee S.Y., Yun C.H., et al. Ictal SPECT in neocortical epilepsies: clinical usefulness and factors affecting the pattern of hyperperfusion. Neuroradiology 2006, 48(9):678-684.
73. Devous M.D., Thisted R.A., Morgan G.F., et al. SPECT brain imaging in epilepsy: a meta-analysis. J Nucl Med 1998, 39(2):285-293.
74. Newton M.R., Berkovic S.F., Austin M.C., et al. Ictal postictal and interictal single-photon emission tomography in the lateralization of temporal lobe epilepsy. Eur J Nucl Med 1994, 21(10):1067-1071.
75. Bartolini A. Regional arm-brain mean transit time in the diagnostic evaluation of patients with cerebral vascular disease. Stroke 1981, 12(2):241-245.
76. Locharernkul C. Factors influencing successful ictal SPECT injections during epilepsy presurgical evaluation. Neurol Asia 2004, 9(Suppl 1):111.
77. O'Brien T.J., So E.L., Mullan B.P., et al. Subtraction ictal SPECT co-registered to MRI improves clinical usefulness of SPECT in localizing the surgical seizure focus. Neurology 1998, 50(2):445-454.
78. Shoeb A., Edwards H., Connolly J., et al. Patient-specific seizure onset detection. Conf Proc IEEE Eng Med Biol Soc 2004, 1:419-422.
79. Henry T.R., Engel J., Mazziotta J.C. Clinical evaluation of interictal fluorine-18-fluorodeoxyglucose PET in partial epilepsy. J Nucl Med 1993, 34(11):1892-1898.
80. Spencer S.S. The relative contributions of MRI, SPECT, and PET imaging in epilepsy. Epilepsia 1994, 35(Suppl 6):S72-S89.
81. Drzezga A., Arnold S., Minoshima S., et al. 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med 1999, 40(5):737-746.
82. Theodore W.H., Sato S., Kufta C., et al. Temporal lobectomy for uncontrolled seizures: the role of positron emission tomography. Ann Neurol 1992, 32(6):789-794.
83. Lin T.W., de Aburto M.A., Dahlbom M., et al. Predicting seizure-free status for temporal lobe epilepsy patients undergoing surgery: prognostic value of quantifying maximal metabolic asymmetry extending over a specified proportion of the temporal lobe. J Nucl Med 2007, 48(5):776-782.
84. Engel J., Pedley T.A. Epilepsy the comprehensive CD-ROM 1999, Lippincott Williams & Wilkins, Philadelphia, p. 1.
85. Hajek M., Antonini A., Leenders K.L., et al. Mesiobasal versus lateral temporal lobe epilepsy: metabolic differences in the temporal lobe shown by interictal 18F-FDG positron emission tomography. Neurology 1993, 43(1):79-86.
86. Ell P.J., Gambhir S.S. Nuclear medicine in clinical diagnosis and treatment 2004, New York, Churchill Livingstone, Edinburgh, 2 v (xxiv, 1924. p. 150). 3rd edition.
87. Carne R.P., Cook M.J., MacGregor L.R., et al. " Magnetic resonance imaging negative positron emission tomography positive" temporal lobe epilepsy: FDG-PET pattern differs from mesial temporal lobe epilepsy. Mol Imaging Biol 2007, 9(1):32-42.
88. Theodore W.H., Holmes M.D., Dorwart R.H., et al. Complex partial seizures: cerebral structure and cerebral function. Epilepsia 1986, 27(5):576-582.
89. la Fougere C., Rominger A., Forster S., et al. PET and SPECT in epilepsy: a critical review. Epilepsy Behav 2009, 15(1):50-55.
90. Lee N., Radtke R.A., Gray L., et al. Neuronal migration disorders: positron emission tomography correlations. Ann Neurol 1994, 35(3):290-297.
91. Cohen-Gadol A.A., Ozduman K., Bronen R.A., et al. Long-term outcome after epilepsy surgery for focal cortical dysplasia. J Neurosurg 2004, 101(1):55-65.
92. Kim S.K., Na D.G., Byun H.S., et al. Focal cortical dysplasia: comparison of MRI and FDG-PET. J Comput Assist Tomogr 2000, 24(2):296-302.
93. Szelies B., Herholz K., Heiss W.D., et al. Hypometabolic cortical lesions in tuberous sclerosis with epilepsy: demonstration by positron emission tomography. J Comput Assist Tomogr 1983, 7(6):946-953.
94. Savic I., Svanborg E., Thorell J.O. Cortical benzodiazepine receptor changes are related to frequency of partial seizures: a positron emission tomography study. Epilepsia 1996, 37(3):236-244.
95. Savic I., Persson A., Roland P., et al. In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 1988, 2(8616):863-866.
96. Henry T.R., Frey K.A., Sackellares J.C., et al. In vivo cerebral metabolism and central benzodiazepine-receptor binding in temporal lobe epilepsy. Neurology 1993, 43(10):1998-2006.
97. Szelies B., Weber-Luxenburger G., Mielke R., et al. Interictal hippocampal benzodiazepine receptors in temporal lobe epilepsy: comparison with coregistered hippocampal metabolism and volumetry. Eur J Neurol 2000, 7(4):393-400.
98. Debets R.M., Sadzot B., van Isselt J.W., et al. Is 11C-flumazenil PET superior to 18FDG PET and 123I-iomazenil SPECT in presurgical evaluation of temporal lobe epilepsy?. J Neurol Neurosurg Psychiatry 1997, 62(2):141-150.
99. Hammers A., Koepp M.J., Hurlemann R., et al. Abnormalities of grey and white matter [11C]flumazenil binding in temporal lobe epilepsy with normal MRI. Brain 2002, 125(Pt 10):2257-2271.
100. Savic I., Thorell J.O., Roland P. [11C]flumazenil positron emission tomography visualizes frontal epileptogenic regions. Epilepsia 1995, 36(12):1225-1232.
101. Hammers A., Koepp M.J., Brooks D.J., et al. Periventricular white matter flumazenil binding and postoperative outcome in hippocampal sclerosis. Epilepsia 2005, 46(6):944-948.
102. Muzik O., da Silva E.A., Juhasz C., et al. Intracranial EEG versus flumazenil and glucose PET in children with extratemporal lobe epilepsy. Neurology 2000, 54(1):171-179.
103. Ryvlin P., Bouvard S., Le Bars D., et al. Transient and falsely lateralizing flumazenil-PET asymmetries in temporal lobe epilepsy. Neurology 1999, 53(8):1882-1885.
104. Bouvard S., Costes N., Bonnefoi F., et al. Seizure-related short-term plasticity of benzodiazepine receptors in partial epilepsy: a [11C]flumazenil-PET study. Brain 2005, 128(Pt 6):1330-1343.
105. Chugani D.C., Chugani H.T., Muzik O., et al. Imaging epileptogenic tubers in children with tuberous sclerosis complex using alpha-[11C]methyl-L-tryptophan positron emission tomography. Ann Neurol 1998, 44(6):858-866.
106. Louw D., Sutherland G.R., Glavin G.B., et al. A study of monoamine metabolism in human epilepsy. Can J Neurol Sci 1989, 16(4):394-397.
107. Pintor M., Mefford I.N., Hutter I., et al. Levels of biogenic amines, their metabolites, and tyrosine hydroxylase activity in the human epileptic temporal cortex. Synapse 1990, 5(2):152-156.
108. Trottier S., Evrard B., Vignal J.P., et al. The serotonergic innervation of the cerebral cortex in man and its changes in focal cortical dysplasia. Epilepsy Res 1996, 25(2):79-106.
109. Missala K., Sourkes T.L. Functional cerebral activity of an analogue of serotonin formed in situ. Neurochem Int 1988, 12(2):209-214.
110. Kagawa K., Chugani D.C., Asano E., et al. Epilepsy surgery outcome in children with tuberous sclerosis complex evaluated with alpha-[11C]methyl-L-tryptophan positron emission tomography (PET). J Child Neurol 2005, 20(5):429-438.